

Form 51-102F3
Material Change Report

MATERIAL CHANGE REPORT UNDER SECTION 7.1 OF NATIONAL INSTRUMENT 51-102

NOTE: WHERE THIS REPORT IS FILED ON A CONFIDENTIAL BASIS PUT AT THE BEGINNING OF THE REPORT IN BLOCK CAPITALS "CONFIDENTIAL".

Item 1. Name and Address of Company

Vodis Pharmaceuticals Inc. (the "Company")
8778 River Road,
Delta, BC,
V4G 1B4

Item 2. Date of Material Change

October 11, 2016

Item 3. News Release

The news release was disseminated through CSE, BC Securities Commission, Ontario Securities Commission, Stockwatch and Market News.

Item 4. Summary of Material Change

Vodis Pharmaceuticals Inc. (CSE: VP / FSE: 1JV) ("**Vodis**" or the "**Company**") is very pleased to announce that Ivan Miliovski who is one of the company's founders has moved from the interim CEO role to full time CEO position. Additionally Vodis is very pleased to announce the appointment of Mark Lotz as their CFO.

Item 5. Full Description of Material Change

Vodis Pharmaceuticals Inc. (CSE: VP / FSE: 1JV) ("**Vodis**" or the "**Company**") is very pleased to announce that Ivan Miliovski who is one of the company's founders has moved from the interim CEO role to full time CEO position. Additionally Vodis is very pleased to announce the appointment of Mark Lotz as their CFO.

Mr Lotz is a Chartered Professional Accountant practicing publicly through his firm Lotz CPA Inc. Having qualified in 1994 he brings a wealth of experience in business, tax and consulting. Formerly a CEO and CFO in the brokerage industry, he also has senior management experience in the mining, manufacturing and digital media sectors. He provides strategic tax and business planning and is a sought after expert for complex contractual issues and financial quantification. He regularly consults with legal firms acting as an expert witness on matters of securities regulation and litigation. He sits on the board of and is chair of the

audit committees for a number of public companies. In addition he serves as the CFO of TrackX Holdings Inc., the Canadian parent of a U.S. based assets tracking solutions provider.

"Mark is an excellent addition to our team and will provide a key analytical approach we need to develop and execute our business model. It's crucial as we expand our business that we grow with the bottom line in mind and we establish a clear picture of what true costs go into every dollar of revenue we can create." states CEO Ivan Miliovski.

Item 6. Reliance on Section 7.1(2) or (3) of National Instrument 51-102

Nothing in this form is required to be maintained on a confidential basis.

Item 7. Omitted Information

Not applicable.

Item 8. Senior Officers

Ivan Miliovski, CEO
Phone: (778) 242-9677

Item 9. Date of Report

Dated at Vancouver this 11th day of October, 2016.

By: Vodis Pharmaceuticals Inc.

“Ivan Miliovski”

Ivan Miliovski, CEO